Abstract：Innate immune cells and adaptive immune cells play an important role in the pathogenesis and development of atherosclerosis （AS）. Innate immune cells include mononuclear macrophages, natural killer cells, neutrophils, dendritic cells and so on. Adaptive immune cells include T lymphocytes and B lymphocytes. These cells promote or inhibit the formation of atherosclerotic plaques through different differentiation phenotypes and the secretion of various cytokines. In-depth understanding the role of immune cells in the AS pathological process is helpful to explore new therapeutic targets and methods for AS.
[1] 世卫组织敦促采取更多行动处理每年非传染性疾病导致的1600万人过早死亡问题[EB/OL].https：//www.who.int/mediacentre/news/releases/2015/noncom-municable-diseases/zh/#.
[2] Kobiyama K，Ley K. Atherosclerosis [J]. Circ Res，2018， 123（10）：1118-1120.
[3] Zhu Y，Xian X，Wang Z，et al. Research Progress on the Relationship between Atherosclerosis and Inflammation [J]. Biomolecules，2018，8（3）：80.
[4] Ketelhuth DF，Hansson GK. Adaptive Response of T and B Cells in Atherosclerosis [J]. Circ Res，2016，118（4）：668-678.
[5] Tabas I，Lichtman AH. Monocyte-Macrophages and T Cells in Atherosclerosis. Immunity [J]. Immunity，2017，47（4）：621-634.
[6] Wang D，Yang Y，Lei Y，et al. Targeting Foam Cell Formation in Atherosclerosis：Therapeutic Potential of Natural Products [J]. Pharmacol Rev，2019，71（4）：596-670.
[7] Jinnouchi H，Guo L，Sakamoto A，et al. Diversity of mac-rophage phenotypes and responses in atherosclerosis [J]. Cell Mol Life Sci，2020，77（10）：1919-1932.
[8] Tian Y，Yang C，Yao Q，et al. Procyanidin B2 Activates PPARγ to Induce M2 Polarization in Mouse Macrophages [J]. Front Immunol，2019，10：1895.
[9] Shapouri-Moghaddam A，Mohammadian S，Vazini H，et al. Macrophage plasticity，polarization，and function in health and disease [J]. J Cell Physiol，2018，233（9）：6425-6440.
[10] Willemsen L，de Winther MP. Macrophage subsets in atherosclerosis as defined by single-cell technologies [J]. J Pathol，2020，250（5）：705-714.
[11] Xu H，Jiang J，Chen W，et al. Vascular Macrophages in Atherosclerosis [J]. J Immunol Res，2019，2019：4354786.
[12] Chistiakov DA，Myasoedova VA，Revin VV，et al. The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2 [J]. Immunobiology，2018，223（1）：101-111.
[13] D?觟ring Y，Soehnlein O，Weber C. Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis [J]. Circ Res，2017，120（4）：736-743.
[14] VanderLaan PA，Reardon CA，Cabana VG，et al. Invariant Natural Killer T-Cells and Total CD1d Restricted Cells Differentially Influence Lipid Metabolism and Athe-rosclerosis in Low Density Receptor Deficient Mice [J]. Int J Mol Sci，2019，20（18）：4566.
[15] Subramanian S，Goodspeed L，Wang S，et al. Deficiency of Invariant Natural Killer T Cells Does Not Protect Against Obesity but Exacerbates Atherosclerosis in Ldlr-/- Mice [J]. Int J Mol Sci，2018，19（2）：510.
[16] Gil-Pulido J，Zernecke A. Antigen-presenting dendritic cells in atherosclerosis [J]. Eur J Pharmacol，2017，816：25-31.
[17] Fernandez DM，Rahman AH，Fernandez NF，et al. Single-cell immune landscape of human atherosclerotic plaques [J]. Nat Med，2019，25（10）：1576-1588.
[18] Kyaw T，Bobik A. Early adaptive CD4+ T-cell immunity in atherosclerosis goes local [J]. Cardiovasc Res，2020， 116（2）：253-255.
[19] ?魡kerblom A，James SK，Lakic TG，et al. Interleukin-18 in patients with acute coronary syndromes [J]. Clin Cardiol，2019，42（12）：1202-1209.
[20] Rogers AJ，Guan J，Trtchounian A，et al. Association of Elevated Plasma Interleukin-18 Level With Increased Mortality in a Clinical Trial of Statin Treatment for Acute Respiratory Distress Syndrome [J]. Crit Care Med，2019， 47（8）：1089-1096.
[21] King VL，Szilvassy SJ，Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice [J]. Arterioscler Thromb Vasc Biol，2002，22（3）： 456-461.
[22] King VL，Cassis LA，Daugherty A. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin Ⅱ-induced atherosclerotic lesions in mice [J]. Am J Pathol，2007，171（6）：2040-2047.
[23] Braddock M，Hanania NA，Sharafkhaneh A，et al. Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling：A Systematic Review [J]. Drug Saf，2018，41（5）：489-509.
[24] Taleb S，Tedgui A. IL-17 in atherosclerosis：the good and the bad [J]. Cardiovasc Res，2018，114（1）：7-9.
[25] Nordlohne J，von Vietinghoff S. Interleukin 17A in ath-erosclerosis-Regulation and pathophysiologic effector function [J]. Cytokine，2019，122：154089.
[26] Yu H，Ma S，Sun L，et al. TGF-β1 upregulates the expression of lncRNA-ATB to promote atherosclerosis [J]. Mol Med Rep，2019，19（5）：4222-4228.
[27] Huo Y，Chu Y，Guo L，et al. Cortisol is associated with low frequency of interleukin 10-producing B cells in patients with atherosclerosis [J]. Cell Biochem Funct，2017，35（3）：178-183.
[28] Ou HX，Guo BB，Liu Q，et al. Regulatory T cells as a new therapeutic target for atherosclerosis [J]. Acta Pharmacol Sin，2018，39（8）：1249-1258.
[29] Filatova AY，Pylaeva EA，Potekhina AV，et al. Low Blood Content of IL-10-Producing CD4+ T Cells as a Risk Factor for Progression of Coronary Atherosclerosis [J]. Bull Exp Biol Med，2019，166（3）：330-333.
[30] Karadimou G，Gister?覽 A，Gallina AL，et al. Treatment with a Toll-like Receptor 7 ligand evokes protective immunity against atherosclerosis in hypercholesterolaemic mice [J]. J Intern Med，2020，288（3）：321-334.
[31] Tay C，Liu YH，Kanellakis P，et al. Follicular B Cells Promote Atherosclerosis via T Cell-Mediated Differentiation into Plasma Cells and Secreting Pathogenic Immunoglobulin G [J]. Arterioscler Thromb Vasc Biol，2018，38（5）：e71-e84.
[32] Tsiantoulas D，Diehl CJ，Witztum JL，et al. B cells and humoral immunity in atherosclerosis [J]. Circ Res，2014， 114（11）：1743-1756.
[33] Centa M，Jin H，Hofste L，et al. Germinal Center-Derived Antibodies Promote Atherosclerosis Plaque Size and Stability [J]. Circulation，2019，139（21）：2466-2482.
[34] Sage AP，Mallat Z. Multiple potential roles for B cells in atherosclerosis [J]. Ann Med，2014，46（5）：297-303.
2020, Vol. 17 
京公网安备 11010502046598号